Place of the novel drug ranolazine in the treatment of coronary artery disease
https://doi.org/10.21518/2079-701X-2014-12-44-48
Abstract
Despite the widely used myocardial revascularization (angioplasty and stenting, aorto- or mammo-coronary bypass), extensive pharmacotherapy aimed at improving the quality of life (through the improvement of exercise tolerance and elimination of angina attacks) and increasing its "quantity", i.e. improving the prognosis, coronary heart disease remains the leading cause of overall mortality in the world and in Russia. In a majority of patients, angina persists even after revascularization of the myocardium, therefore they still need antianginal therapy. [1] Additionally, for some patients revascularization is not possible because of anatomical features of coronary vessels and contraindications to medicines traditionally used in angioplasty.
About the Authors
GA BaryshnikovaRussian Federation
SA Chorbinskaya
Russian Federation
И. II Stepanova
Russian Federation
References
1. Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика, 2008, 6 (прил. 4): 1-40.
2. Berger P. Ranolazine and other antianginal therapies in era of the drug-eluting stent.JAMA, 2004, 291 (3): 365-367.
3. Bassand J-P. Clinical implications of inhibitor of the late sodium current: ranolazine. Eur Heart J, 2006, 8 (Suppl. A): A14-A19.
4. Aslam S., Gray D. Ranolazine (Renexa) in the treatment of chronic stable angina. Advances in Therapy, 2010, 27 (4): 193-201.
5. Patel P.D., Arora R.R. Utility of ranolazine in chronic stable angina patients. Cardiovasc Health Risk Manag, 2008, 4 (4): 819-824.
6. Lopaschuk GD, Kantor PF, Dyck JRB. Optimizing cardiac metabolism: a new reference approach in the management of ischemic heart disease? Medicographia, 1999, 21 (2):109-115.
7. Anderson JR, Nawarskas JJ. Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Cardiol Rev, 2005, 13; 202-210.
8. Rousseau MF, Pouleur H, Cocco G, Wolff AF. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. AmJ Cardiol, 2005, 95: 311-316.
9. Chaitman BR, Skettino SL, Parker JO et al. for the MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol, 2004, 43: 1375-1382.
10. Stone PH, Gratsiansky NA, Blokhin A et al. for the ERICA investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol, 2006, 48: 566-575.
11. Chaitman BR, Pepine CJ, Parker JO et al. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.JAMA, 2004, 291: 309-316.
12. Timmis AD, et al. Eur Heart J, 2006, 27: 42-8.
13. Wilson SR, Scirica BM, Braunwald E ct al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) Trial. J Am Coll Cardiol, 2009, 53 (17): 1510-1516.
14. Morrow DA, Scirica BM, Chaitman BR et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation, 2009, Apr. 21, 119: 2032-2039.
15. Koren MJ et al. J Am Coll Cardiol, 2007, 49: 1027-34.
16. Jerling M, Huan BL, Leung K et al. Studies to investigate the pharmacokinetic interaction between ranolazine and ketoconazole, diltiazem or simvastatin during combined administration in healthy subjects. J Clin Pharmacol, 2005, 45: 422-433.
17. Keating G.M. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs, 2008, 68 (17): 2483-2503.
Review
For citations:
Baryshnikova G, Chorbinskaya S, Stepanova I. Place of the novel drug ranolazine in the treatment of coronary artery disease. Meditsinskiy sovet = Medical Council. 2014;(12):44-48. (In Russ.) https://doi.org/10.21518/2079-701X-2014-12-44-48
Views:
435
Email this article 